Infants with ARIH typically present with symptoms related to high calcium levels. These may include poor feeding, vomiting, dehydration, irritability, and failure to thrive. In severe cases, hypercalcemia can lead to more serious complications such as kidney stones, nephrocalcinosis (calcium deposits in the kidneys), and even renal failure. Some infants may also exhibit hypotonia (reduced muscle tone) and developmental delays.

The diagnostic workup for ARIH involves a combination of clinical evaluation, laboratory tests, and genetic analysis. Blood tests are essential to measure calcium, phosphate, and parathyroid hormone (PTH) levels. Elevated calcium and low PTH levels are indicative of the condition. Genetic testing can confirm the diagnosis by identifying mutations in the CYP24A1 or SLC34A1 genes, which are responsible for ARIH. Imaging studies, such as renal ultrasound, may be conducted to assess kidney involvement.

The primary goal of treatment for ARIH is to manage hypercalcemia and prevent complications. Initial management may include dietary modifications, such as reducing calcium and vitamin D intake. In more severe cases, medications like bisphosphonates or corticosteroids may be used to lower calcium levels. Hydration is crucial to prevent kidney damage, and in some instances, dialysis may be necessary. Regular monitoring of calcium levels and kidney function is essential to adjust treatment as needed.

The prognosis for infants with ARIH varies depending on the severity of the condition and the timeliness of treatment. With appropriate management, many children can lead healthy lives without significant long-term complications. However, if left untreated, severe hypercalcemia can lead to permanent kidney damage and other health issues. Early diagnosis and intervention are key to improving outcomes.

ARIH is caused by mutations in the CYP24A1 or SLC34A1 genes. These genes play a crucial role in regulating calcium and phosphate metabolism. The condition follows an autosomal recessive inheritance pattern, meaning that an affected individual must inherit two copies of the mutated gene, one from each parent. Carriers, who have only one copy of the mutation, typically do not exhibit symptoms.

ARIH is a rare disorder, with only a limited number of cases reported worldwide. The exact prevalence is unknown, but it is considered to be more common in populations with a higher rate of consanguinity (marriage between close relatives). Due to its rarity, ARIH may be underdiagnosed or misdiagnosed as other more common causes of hypercalcemia.

The pathophysiology of ARIH involves disruptions in the normal regulation of calcium and phosphate levels in the body. Mutations in the CYP24A1 gene impair the breakdown of active vitamin D, leading to increased calcium absorption from the gut and elevated blood calcium levels. Mutations in the SLC34A1 gene affect phosphate transport in the kidneys, further contributing to the imbalance of minerals.

Currently, there are no specific measures to prevent ARIH, as it is a genetic condition. However, genetic counseling can be beneficial for families with a history of the disorder. Carrier testing and prenatal diagnosis may be options for at-risk couples to understand their chances of having an affected child.

Autosomal Recessive Infantile Hypercalcemia is a rare genetic disorder characterized by elevated calcium levels in infants. It results from mutations in genes that regulate calcium metabolism. Early diagnosis and management are crucial to prevent complications and improve outcomes. Treatment focuses on controlling hypercalcemia through dietary changes, medications, and regular monitoring.

If your child has been diagnosed with Autosomal Recessive Infantile Hypercalcemia, it's important to work closely with your healthcare team to manage the condition. Treatment may involve dietary adjustments and medications to control calcium levels. Regular follow-up appointments are essential to monitor your child's progress and adjust treatment as needed. Genetic counseling can provide valuable information for family planning and understanding the inheritance pattern of the disorder.